AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.035

+0.0012.94%

Volume:1.70M

Turnover:57.06K

Market Cap:57.13M

PE:-6.49

High:0.035

Open:0.034

Low:0.033

Close:0.034

52wk High:0.095

52wk Low:0.023

Shares:1.63B

Float Shares:1.00B

Volume Ratio:1.74

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.005

EPS(LYR):-0.005

ROE:-118.44%

ROA:-49.40%

PB:3.57

PE(LYR):-6.49

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study

MT Newswires Live

Syntara Ltd-Company Secretary Appointment/Resignation

THOMSON REUTERS

Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder

MT Newswires Live

Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNT.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.035,"timestamp":1770354720000,"preClose":0.034,"halted":0,"volume":1701972,"delay":0,"changeRate":0.029411764705882377,"nameEN":"Syntara Ltd","floatShares":1004676595,"shares":1632399195,"eps":-0.005389,"marketStatus":"Market Closed","change":0.001,"latestTime":"02-06 16:12:00 AEDT","open":0.034,"high":0.035,"low":0.033,"amount":57056,"amplitude":0.058824,"askPrice":0.035,"askSize":660940,"bidPrice":0.034,"bidSize":156867,"shortable":3,"etf":0,"ttmEps":-0.005389,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.034,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":1.7437312241010159,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":1004676595,"roa":"-49.40%","roe":"-118.44%","lyrEps":-0.005389,"volumeRatio":1.7437312241010159,"shares":1632399195,"dividePrice":0,"high":0.035,"amplitude":0.058824,"preClose":0.034,"low":0.033,"week52Low":0.023,"pbRate":"3.57","psRate":"7.83","week52High":0.095,"institutionHeld":0,"latestPrice":0.035,"committee":-0.616372,"eps":-0.005389,"divideRate":0,"volume":1701972,"delay":0,"ttmEps":-0.005389,"open":0.034,"prevYearClose":0.035,"prevWeekClose":0.032,"prevMonthClose":0.032,"prevQuarterClose":0.035,"fiveDayClose":0.032,"twentyDayClose":0.033,"sixtyDayClose":0.029},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-01","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746057600000,"name":null,"time":"","dateTimestamp":1746021600000,"actualEps":null},{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605122162","title":"Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2605122162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605122162?lang=en_us&edition=fundamental","pubTime":"2026-01-21 12:07","pubTimestamp":1768968426,"startTime":"0","endTime":"0","summary":"Syntara  said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","XKO.AU","SNT.AU","BK7096"],"gpt_icon":0},{"id":"2601451339","title":"Syntara Ltd-Company Secretary Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601451339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601451339?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:03","pubTimestamp":1767841419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUE59WMJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","SNT.AU"],"gpt_icon":0},{"id":"2601387057","title":"Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387057","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601387057?lang=en_us&edition=fundamental","pubTime":"2026-01-08 08:14","pubTimestamp":1767831259,"startTime":"0","endTime":"0","summary":"Syntara  enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.The company expects top-line results from the study in the second quarter, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096","REM"],"gpt_icon":0},{"id":"2587616759","title":"Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587616759","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587616759?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:54","pubTimestamp":1764370467,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-snt/syntara-shares/news/is-syntara-asxsnt-in-a-good-position-to-deliver-on-growth-pl-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-snt/syntara-shares/news/is-syntara-asxsnt-in-a-good-position-to-deliver-on-growth-pl-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","SNT.AU","SNT","BK4157"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SNT.AU\",params:#limit:6,delay:true,,,undefined,":[]}}